Action:
Removal of DEA-X Waiver
Action 6417
General Information
| Action Summary |
This action removes the federal requirement that practitioners obtain a special federal waiver, referred to as “X-Waiver” (or “DEA-X Waiver” or “Buprenorphine Waiver”) to prescribe buprenorphine for the treatment of opioid use disorder, pursuant to Section 1262 of the Consolidated Appropriations Act, 2023. |
| Chapters Affected |
Only affects this chapter.
|
| Executive Branch Review |
This Action is exempt from Article 2 of the Administrative Process Act, but falls within the Executive Branch and
will be reviewed by the Governor's Office.
|
| RIS Project |
Yes [7772] |
|
Is Federal action a driving factor in this regulatory change? If so, please provide a specific reference to the law, regulation
or court case.
Section 1262 of the Consolidated Appropriations Act, 2023.
|
| New Periodic Review |
This action will not be used to conduct a new periodic review.
|
Stages
Stages associated with this regulatory action.
| Stage ID |
Stage Type |
Status |
|
10256
|
Final
|
Final Adoption period is underway and will end on 10/23/2024. |
Contact Information
|
Name / Title:
|
Meredith Lee
/
Policy, Regulations, and Manuals Supervisor
|
|
Address:
|
600 E. Broad St., Suite 1300
Richmond, VA 23219
|
|
Email Address:
|
Meredith.Lee@dmas.virginia.gov
|
|
Phone:
|
(804)371-0552
FAX: (804)786-1680
TDD: (800)343-0634
|
